Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms. 1989

A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie

Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity. In indolent lymphocytic leukemia or lymphoma with low ADA concentrations, this drug is effective at low doses with mild toxicity. The on-going EORTC trial shows that pentostatin is highly effective in hairy cell leukemia and can achieve durable complete remissions even if interferon alpha has failed. It will probably play an important role in the treatment of prolymphocytic leukemia, T- and B-cell chronic lymphocytic leukemia and Sézary syndrome.

UI MeSH Term Description Entries
D007943 Leukemia, Hairy Cell A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. Hairy Cell Leukemia,Leukemic Reticuloendotheliosis,Reticuloendotheliosis, Leukemic,Hairy Cell Leukemias,Leukemias, Hairy Cell,Leukemic Reticuloendothelioses,Reticuloendothelioses, Leukemic
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D003070 Coformycin A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant.
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012263 Ribonucleosides Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed)
D012751 Sezary Syndrome A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells). Erythroderma, Sezary,Sezary's Lymphoma,Lymphoma, Sezary's,Sezary Erythroderma,Sezary Lymphoma,Sezarys Lymphoma,Syndrome, Sezary

Related Publications

A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
February 1984, Scandinavian journal of haematology,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
May 1988, Annals of internal medicine,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
March 2005, Haematologica,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
October 1988, Journal of the American Academy of Dermatology,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
June 1997, Journal of the American Academy of Dermatology,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
April 1999, British journal of haematology,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
January 1989, Bone marrow transplantation,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
April 1986, Cancer treatment reports,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
January 1995, Cell transplantation,
A D Ho, and J Thaler, and R Willemze, and F Lauria, and G Derossi, and R Kuse, and P Stryckmans, and C M Blanc, and F Cataldo, and G McVie
February 2006, Leukemia & lymphoma,
Copied contents to your clipboard!